Cytiva strengthens cell line development with CEVEC acquisition


Cytiva acquisition of CEVEC Pharmaceuticals with 46 scientific experts based in Cologne, Germany will join the Cytiva team in the genomic medicine space. Cytiva customers will have immediate access to technologies that solve some of the greatest challenges in bringing gene therapies to patients.

Article Summary

Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies. CEVEC will further strengthen Cytiva’s leading position in biomanufacturing solutions.

A major challenge for the pharmaceutical industry in cell and gene therapy is maintaining consistent quality of viral vectors while meeting ever-increasing volumes. For the delivery of therapeutic genes to target cells and tissues, CEVEC has scalable producer cell lines for Adeno-Associated Virus (AAV) and Adenovirus vectors.

Emmanuel Abate, President, Genomic Medicine at Cytiva, says: “Cevec’s innovative technology complements Cytiva’s offering and brings the promise of improved viral vector manufacturing. With Cytiva’s global reach and ability to scale, more customers will have access to Cevec’s technology and expertise to help accelerate and advance therapeutics for the benefit of patients.”

Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals, says: “We are excited to become part of Cytiva. Combined with Cytiva’s global presence and leading brands, this enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need.”

Producer Cell Lines(PCLs) as enabled by CEVEC’s ELEVECTA® Technology enable yield, scalability, and robustness in the manufacturing process. With the ELEVECTA® Technology, all components necessary for vector production are stably integrated into the genome of the PCL, offering an alternative to technologies based on transfection or the use of a helper virus.


About Cytiva

Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.


(Source: Cytiva, October 6, 2022)


Leave A Comment

Leave a Reply

Your email address will not be published.